Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Assets Average (2018 - 2025)

BioXcel Therapeutics has reported Assets Average over the past 4 years, most recently at $44.9 million for Q4 2025.

  • For Q4 2025, Assets Average rose 2.84% year-over-year to $44.9 million; the TTM value through Dec 2025 reached $44.9 million, up 2.84%, while the annual FY2025 figure was $41.6 million, 25.69% down from the prior year.
  • Assets Average for Q4 2025 was $44.9 million at BioXcel Therapeutics, up from $35.3 million in the prior quarter.
  • Over five years, Assets Average peaked at $246.5 million in Q3 2022 and troughed at $32.2 million in Q2 2025.
  • A 4-year average of $118.2 million and a median of $82.5 million in 2023 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: crashed 61.36% in 2023 and later grew 2.84% in 2025.
  • Year by year, Assets Average stood at $225.3 million in 2022, then crashed by 61.36% to $87.1 million in 2023, then tumbled by 49.91% to $43.6 million in 2024, then grew by 2.84% to $44.9 million in 2025.
  • Business Quant data shows Assets Average for BTAI at $44.9 million in Q4 2025, $35.3 million in Q3 2025, and $32.2 million in Q2 2025.